Comparative Effectiveness of Osteoporosis Medications Among Female Medicare Fee-For-Service (FFS) Beneficiaries in the United States (20210028)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/49180
• EU PAS number:
  EUPAS49101
• Study ID:
  49180
• Official title and acronym:
  Comparative Effectiveness of Osteoporosis Medications Among Female Medicare Fee-For-Service (FFS) Beneficiaries in the United States (20210028)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Finalised

Research institutions and networks

Institutions

Amgen

United States

Study timelines

Date when funding contract was signed

Planned: 22/02/2022

Actual: 21/02/2022

Study start date

Planned: 30/09/2022

Actual: 03/10/2022

Data analysis start date

Planned: 30/09/2022

Actual: 03/10/2022

Date of final study report

Planned: 01/12/2023

Actual: 24/01/2024

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

20210028